Thomas Stankovich - 31 May 2022 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Issuer symbol
RSLS
Transactions as of
31 May 2022
Net transactions value
+$18,422
Form type
4
Filing time
01 Jun 2022, 14:18:18 UTC
Previous filing
12 May 2022
Next filing
06 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Purchase $67.86 +78 +0.02% $0.8700 345,705 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $2,552 +2,900 +0.84% $0.8800 348,605 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $178 +200 +0.06% $0.8900 348,805 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $900 +1,000 +0.29% $0.9000 349,805 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $7,355 +7,995 +2.3% $0.9200 357,800 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $55.8 +60 +0.02% $0.9300 357,860 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $6,147 +6,539 +1.8% $0.9400 364,399 31 May 2022 Direct
transaction RSLS Common Stock, $0.001 par value per share Purchase $1,167 +1,228 +0.34% $0.9500 365,627 31 May 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.